A crucial role for novel miR-12137-3p in supporting weight gain in treatment naïve HIV-infected patients on antiretroviral therapies

Puntos clave

• The study aims to explore the impact of miR-12137-3p on weight gain in HIV-infected patients who are treatment naïve.
• Conducted a clinical trial registered on ClinicalTrials.gov.
• Monitored weight changes in HIV-infected patients beginning antiretroviral therapies.
• Analyzed the expression levels of miR-12137-3p in relation to weight gain.
• Identified a significant correlation between miR-12137-3p levels and weight gain.
• Demonstrated that higher levels of miR-12137-3p are associated with increased weight gain during treatment.
• Found potential for miR-12137-3p as a biomarker for weight management in this population.